Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects
Phase of Trial: Phase IV
Latest Information Update: 16 Sep 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Fluart Innovative Vaccines; Omninvest
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-002379-32).
- 22 Aug 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.